FBXO32 and cardiac hypertrophy: Furthermore, LPS is known to directly induce cardiomyocyte hypertrophy through activation of calcineurin signaling pathway [49], whereas overexpression of atrogin-1 promotes calcineurin degradation and inhibits its activity, resulting in inhibition of cardiac hypertrophy [5].